RU96110892A - PSEUDDODIPEPTIDY PRODUCT CONTAINING IMIDAZOLIC GROUP, AND ITS APPLICATION - Google Patents
PSEUDDODIPEPTIDY PRODUCT CONTAINING IMIDAZOLIC GROUP, AND ITS APPLICATIONInfo
- Publication number
- RU96110892A RU96110892A RU96110892/04A RU96110892A RU96110892A RU 96110892 A RU96110892 A RU 96110892A RU 96110892/04 A RU96110892/04 A RU 96110892/04A RU 96110892 A RU96110892 A RU 96110892A RU 96110892 A RU96110892 A RU 96110892A
- Authority
- RU
- Russia
- Prior art keywords
- paragraphs
- product
- radical
- pseudodipeptide
- product according
- Prior art date
Links
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 9
- 229940079593 drugs Drugs 0.000 claims 9
- -1 hydrocarbon radical Chemical group 0.000 claims 9
- 235000008206 alpha-amino acids Nutrition 0.000 claims 8
- 239000004215 Carbon black (E152) Substances 0.000 claims 7
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims 7
- 238000002360 preparation method Methods 0.000 claims 7
- 125000000524 functional group Chemical group 0.000 claims 6
- 229960001340 histamine Drugs 0.000 claims 6
- 210000001519 tissues Anatomy 0.000 claims 6
- 150000001412 amines Chemical class 0.000 claims 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 4
- 239000010452 phosphate Substances 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 4
- 229910052727 yttrium Inorganic materials 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 230000021615 conjugation Effects 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 210000003491 Skin Anatomy 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 2
- 125000004429 atoms Chemical group 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 150000003951 lactams Chemical class 0.000 claims 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 2
- 229910052725 zinc Inorganic materials 0.000 claims 2
- 239000011701 zinc Substances 0.000 claims 2
- NTSCIJOQEQIATB-VIFPVBQESA-N (2S)-N-[2-(1H-imidazol-5-yl)ethyl]pyrrolidine-2-carboxamide Chemical group O=C([C@H]1NCCC1)NCCC1=CNC=N1 NTSCIJOQEQIATB-VIFPVBQESA-N 0.000 claims 1
- LHJGJYXLEPZJPM-UHFFFAOYSA-N 2,4,5-trichlorophenol Chemical compound OC1=CC(Cl)=C(Cl)C=C1Cl LHJGJYXLEPZJPM-UHFFFAOYSA-N 0.000 claims 1
- PDOIGRRPKSYVKH-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O.OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O PDOIGRRPKSYVKH-UHFFFAOYSA-N 0.000 claims 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 claims 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-Nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 claims 1
- CTQMJYWDVABFRZ-UHFFFAOYSA-N 5-chloroquinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=C(Cl)C2=C1 CTQMJYWDVABFRZ-UHFFFAOYSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 229940009098 Aspartate Drugs 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 229940001468 Citrate Drugs 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010067410 Endotoxaemia Diseases 0.000 claims 1
- 210000001508 Eye Anatomy 0.000 claims 1
- 210000001156 Gastric Mucosa Anatomy 0.000 claims 1
- 229940049906 Glutamate Drugs 0.000 claims 1
- 102000004157 Hydrolases Human genes 0.000 claims 1
- 108090000604 Hydrolases Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 210000001117 Keloid Anatomy 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 206010025135 Lupus erythematosus Diseases 0.000 claims 1
- 210000004400 Mucous Membrane Anatomy 0.000 claims 1
- LKPFBGKZCCBZDK-UHFFFAOYSA-N N-Hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 claims 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 1
- 108009000578 Oxidative Stress Proteins 0.000 claims 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N Pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 claims 1
- 102000035443 Peptidases Human genes 0.000 claims 1
- 108091005771 Peptidases Proteins 0.000 claims 1
- 206010036181 Porphyria Diseases 0.000 claims 1
- 241000097929 Porphyria Species 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- 206010040882 Skin lesion Diseases 0.000 claims 1
- 208000010110 Spontaneous Platelet Aggregation Diseases 0.000 claims 1
- 210000002784 Stomach Anatomy 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001371 alpha-amino acids Chemical class 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 125000004069 aziridinyl group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims 1
- 229910052803 cobalt Inorganic materials 0.000 claims 1
- 239000010941 cobalt Substances 0.000 claims 1
- 229960005188 collagen Drugs 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002255 enzymatic Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000011737 fluorine Chemical group 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 229940050410 gluconate Drugs 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 102000004882 lipase Human genes 0.000 claims 1
- 108090001060 lipase Proteins 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- PWHULOQIROXLJO-UHFFFAOYSA-N manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims 1
- 229910052748 manganese Inorganic materials 0.000 claims 1
- 239000011572 manganese Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229910052759 nickel Inorganic materials 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 125000005254 oxyacyl group Chemical group 0.000 claims 1
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 1
- 229940075930 picrate Drugs 0.000 claims 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 150000003141 primary amines Chemical class 0.000 claims 1
- 239000000718 radiation-protective agent Substances 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000003716 rejuvenation Effects 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 150000003335 secondary amines Chemical class 0.000 claims 1
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atoms Chemical group 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 230000002194 synthesizing Effects 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 150000003568 thioethers Chemical class 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 229960005486 vaccines Drugs 0.000 claims 1
- 201000011528 vascular disease Diseases 0.000 claims 1
- 150000003953 γ-lactams Chemical class 0.000 claims 1
- 150000003954 δ-lactams Chemical class 0.000 claims 1
Claims (32)
в которой А представлен а) либо в форме
где В представляет собой амин, в котором атом азота напрямую связан с углеродным атомом и выбран из группы, состоящей из 1) первичного амина; 2) вторичного амина, имеющего формулу -NH-X-, в которой Х является углеводородным радикалом, фторалкилом, или ацилом, или амином; 3) четвертичным циклическим амином циклоалкильного типа или лактамом; 4) четвертичным амином с формулой в которой Y или Y' являются углеводородным радикалом, ацилом или оксиацилом; 5) амином с формулой в которой Y является углеводородным радикалом и Y' является атомом водорода или углеводородным радикалом; 6) аммонием с формулой
в которой Y, Y', Y'' являются углеводородными радикалами и ион W является галогенидом, сульфатом, фосфатом, бикарбонатом, паратолуол-сульфонатом, или соединением, содержащим карбоксильную кислотную группу.1. Pseudodipeptide product having the general formula
in which A is represented a) either in the form
where B represents an amine in which the nitrogen atom is directly linked to the carbon atom and is selected from the group consisting of 1) a primary amine; 2) a secondary amine having the formula —NH — X—, in which X is a hydrocarbon radical, fluoroalkyl, or acyl, or amine; 3) quaternary cyclic amine of cycloalkyl type or lactam; 4) Quaternary amine with the formula wherein Y or Y ′ is a hydrocarbon radical, acyl or oxyacyl; 5) amine with the formula in which Y is a hydrocarbon radical and Y 'is a hydrogen atom or a hydrocarbon radical; 6) ammonium with the formula
wherein Y, Y ′, Y ″ are hydrocarbon radicals, and W ion is a halide, sulfate, phosphate, bicarbonate, para-toluene sulfonate, or a compound containing a carboxylic acid group.
R' является атомом водорода, атомом фтора, алкильным радикалом, или фтор-алкильным радикалом.R is a fluorine atom, a fluoroalkyl radical, a functional group such as a sulfate, a phosphate or a carboxylic acid group, an acyl radical, a linear alkyl chain that may be substituted by one or more functional groups, or an alkenyl or aryl radical, which may be substituted with one or several functional groups
R 'is a hydrogen atom, a fluorine atom, an alkyl radical, or a fluoro-alkyl radical.
где R является атомом водорода, или фтора, или фтор-алкил радикалом, ацилом или углеводородным радикалом, способным к замещению одной или несколькими функциональными группами, и
R'' является ацильным радикалом или углеводородным радикалом, который может быть замещен одной или несколькими функциональными группами.Im is imidazole or N-substituted imidazole, b) either in the form
where R is a hydrogen atom, or fluorine, or a fluoro-alkyl radical, acyl or hydrocarbon radical, capable of replacing one or more functional groups, and
R "is an acyl radical or a hydrocarbon radical, which may be substituted by one or more functional groups.
где псевдодипептидный продукт является L-пролил-гистамином.11. The pseudodipeptide product according to claim 1 or 2, characterized in that it has the general formula in the form b) R ″ is a CH 2 —CH 2 —CH 2 radical, and thus when A is
where the pseudodipeptide product is L-prolyl-histamine.
N-концевая защита α-аминокислоты группой Х;
О-активация α-аминокислоты группой Y;
сопряжение N-защищенной и О-активированной α-аминокислоты с гистамином или метил-замещенным гистамином;
удаление или сохранение Х в соответствии с желаемым псевдодипептидным продуктом.13. The method of obtaining the product, in PP. 1 - 11, characterized in that it includes the following steps:
N-terminal α-amino acid protection by X group;
O-activation of α-amino acids by the group Y;
conjugation of N-protected and O-activated α-amino acid with histamine or methyl-substituted histamine;
removing or retaining X in accordance with the desired pseudodipeptide product.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR93/13480 | 1993-11-05 | ||
FR9313480A FR2711990B1 (en) | 1993-11-05 | 1993-11-05 | Pseudodipeptide product having an imidazole group, and therapeutic, cosmetological and agrifood applications. |
Publications (2)
Publication Number | Publication Date |
---|---|
RU96110892A true RU96110892A (en) | 1998-09-27 |
RU2159775C2 RU2159775C2 (en) | 2000-11-27 |
Family
ID=9452766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU96110892/04A RU2159775C2 (en) | 1993-11-05 | 1994-11-03 | Pseudopeptide product containing imidazole group and utilization thereof |
Country Status (17)
Country | Link |
---|---|
US (1) | US6046340A (en) |
EP (1) | EP0726895B1 (en) |
JP (1) | JP3503899B2 (en) |
KR (1) | KR100363812B1 (en) |
CN (1) | CN1056608C (en) |
BR (1) | BR9407971A (en) |
CA (1) | CA2174526C (en) |
CZ (1) | CZ292108B6 (en) |
DE (1) | DE69425153T2 (en) |
ES (1) | ES2149951T3 (en) |
FR (1) | FR2711990B1 (en) |
GR (1) | GR3034543T3 (en) |
HU (1) | HU222566B1 (en) |
PT (1) | PT726895E (en) |
RU (1) | RU2159775C2 (en) |
UA (1) | UA56123C2 (en) |
WO (1) | WO1995012581A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5786326A (en) * | 1995-02-03 | 1998-07-28 | Horwitz; Lawrence D. | Method for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation |
ES2170859T3 (en) * | 1995-05-30 | 2002-08-16 | Gliatech Inc | DERIVATIVES OF IMIDAZOL 1H-4 (5) - REPLACED. |
RU2141483C1 (en) * | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Peptide derivatives or their pharmaceutically acceptable salts, method of their synthesis, use and pharmaceutical composition |
FR2769838B1 (en) * | 1997-10-16 | 2000-04-07 | Roc Sa | USE OF NITROGEN DERIVATIVES FOR THE PREPARATION OF A DERMATOLOGICAL OR COSMETOLOGICAL COMPOSITION |
FR2778562B1 (en) * | 1998-05-14 | 2000-08-04 | Sephra | PHARMACEUTICAL, HYGIENIC AND / OR COSMETIC COMPOSITION CONTAINING SEAWATER AND ARGININE |
KR100598723B1 (en) * | 1998-07-14 | 2006-07-11 | 알콘 매뉴팩츄어링, 리미티드 | Use of 11-3-dimethylaminopropylidene-6,11-dihydrodibenz [b,e]oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization |
US6417397B1 (en) | 1999-10-04 | 2002-07-09 | The Regents Of The University Of California, San Diego | N-substituted alkylamino acids for use as amino-protecting groups |
EP1125925A1 (en) * | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
AU5355501A (en) | 2000-04-14 | 2001-10-30 | Niadyne Corp | Method for identifying regulators of protein-advanced glycation end product (protein-age) formation |
US20040131643A1 (en) * | 2001-03-05 | 2004-07-08 | Harleen Grewal | Immune response potentiation |
MC200060A1 (en) | 2002-10-04 | 2003-05-28 | M Exsymol Sa | Coupling product between tryptamine and an alpha-amino acid, its preparation process and its application in the field of neuro-cosmetics |
CA2670590C (en) * | 2006-12-01 | 2018-06-12 | Wake Forest University Health Sciences | Medical devices incorporating collagen inhibitors |
FR2992644B1 (en) | 2012-07-02 | 2015-07-03 | Exsymol Sa | FAMILY OF POLYAMINE ARYLETHYLAMIDE COMPOUNDS, AND THEIR COSMETIC OR DERMOCOSMETIC APPLICATIONS |
MC200154A1 (en) * | 2012-07-02 | 2013-01-23 | Exsymol Sa | Family of arylethylamides polyamino compounds, and their cosmetic or dermocosmetic applications |
JP6326601B2 (en) | 2013-03-13 | 2018-05-23 | アンティース ソシエテ アノニム | Peptides for skin renewal and methods of using said peptides |
WO2015114176A1 (en) * | 2014-01-31 | 2015-08-06 | Dermopartners, S.L. | Cosmetic product with anti-skin-aging properties |
WO2022016343A1 (en) * | 2020-07-20 | 2022-01-27 | 深圳迈瑞生物医疗电子股份有限公司 | Use of composition for platelet disaggregation, disaggregation reagent, and disaggregation method |
CN114989091A (en) * | 2022-06-14 | 2022-09-02 | 水羊化妆品制造有限公司 | Preparation method of glutamyl ethyl imidazole |
CN117143022A (en) * | 2023-08-30 | 2023-12-01 | 上海克琴科技有限公司 | Synthesis method of glutaminyl ethyl imidazole |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2301532A (en) * | 1938-08-18 | 1942-11-10 | Parke Davis & Co | Biological product and process of obtaining same |
US2581814A (en) * | 1947-10-04 | 1952-01-08 | Ralph L Evans | Preparation of glutamyl histidine |
US4613676A (en) * | 1983-11-23 | 1986-09-23 | Ciba-Geigy Corporation | Substituted 5-amino-4-hydroxyvaleryl derivatives |
EP0144290A3 (en) * | 1983-12-01 | 1987-05-27 | Ciba-Geigy Ag | Substituted ethylenediamine derivatives |
US4996221A (en) * | 1987-01-13 | 1991-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Histamine derivatives as immune modulators |
IL92441A (en) * | 1988-12-07 | 1993-05-13 | Tanabe Seiyaku Co | Imidazole containing peptides, their preparation and pharmaceutical compositions containing them |
US4962120A (en) * | 1989-03-22 | 1990-10-09 | Sterling Drug Inc. | 1H-imidazole-1-acetamides |
FR2701948B1 (en) * | 1993-02-22 | 1996-07-26 | Exsymol Sa | Coupling product of histamine or methyl-substituted histamine and an amino acid, process for preparation and therapeutic, cosmetic and food applications. |
-
1993
- 1993-11-05 FR FR9313480A patent/FR2711990B1/en not_active Expired - Lifetime
-
1994
- 1994-03-11 UA UA96041709A patent/UA56123C2/en unknown
- 1994-11-03 JP JP51305195A patent/JP3503899B2/en not_active Expired - Fee Related
- 1994-11-03 RU RU96110892/04A patent/RU2159775C2/en active
- 1994-11-03 CN CN94194386A patent/CN1056608C/en not_active Expired - Lifetime
- 1994-11-03 ES ES95900185T patent/ES2149951T3/en not_active Expired - Lifetime
- 1994-11-03 PT PT95900185T patent/PT726895E/en unknown
- 1994-11-03 CA CA002174526A patent/CA2174526C/en not_active Expired - Lifetime
- 1994-11-03 US US08/637,790 patent/US6046340A/en not_active Expired - Lifetime
- 1994-11-03 CZ CZ19961155A patent/CZ292108B6/en not_active IP Right Cessation
- 1994-11-03 HU HU9600989A patent/HU222566B1/en not_active IP Right Cessation
- 1994-11-03 KR KR1019960702354A patent/KR100363812B1/en not_active IP Right Cessation
- 1994-11-03 DE DE69425153T patent/DE69425153T2/en not_active Expired - Lifetime
- 1994-11-03 WO PCT/FR1994/001272 patent/WO1995012581A1/en active IP Right Grant
- 1994-11-03 BR BR9407971A patent/BR9407971A/en not_active Application Discontinuation
- 1994-11-03 EP EP95900185A patent/EP0726895B1/en not_active Expired - Lifetime
-
2000
- 2000-10-04 GR GR20000402233T patent/GR3034543T3/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU96110892A (en) | PSEUDDODIPEPTIDY PRODUCT CONTAINING IMIDAZOLIC GROUP, AND ITS APPLICATION | |
KR960705785A (en) | Pseudodipeptide compound having an imidazole group and a method for preparing and using the same | |
US10314802B2 (en) | Isoprenyl compounds and methods thereof | |
JP3510627B2 (en) | Use of N-arylmethyleneethylenediaminetriacetate, N-arylmethyleneiminodiacetate or N, N'-diarylmethyleneethylenediamine acetate for oxidative stress | |
DD201777A5 (en) | METHOD FOR PRODUCING NEW PEPTIDES | |
RU95118405A (en) | PRODUCT OF CONDENSATION OF HISTAMINE OR METHYL SUBSTITUTED HISTAMINE AND AMINO ACID, THE PROCESS OF PREPARATION AND APPLICATION IN THERAPY, COSMETOLOGY, AGRICULTURE AND FOOD AREAS | |
JP3373852B2 (en) | Coupling products obtained from histamine and amino acids | |
US5571889A (en) | Polymer containing monomer units of chemically modified polyaspartic acids or their salts and process for preparing the same | |
US20120252866A1 (en) | Age Inhibitors | |
US20040161483A1 (en) | Treating method for suppressing hair growth | |
JP2948658B2 (en) | Novel amino acid derivative, production method thereof and pharmaceutical composition thereof | |
FR2546164A1 (en) | NOVEL PEPTIDE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION AS ELASTASE INHIBITORS | |
KR20060113110A (en) | A hydroxamic acid derivative and the preparation method thereof | |
CA2109599A1 (en) | Lipopolyaminoacids, preparation and uses thereof | |
JPS6320820B2 (en) | ||
JPH0848766A (en) | Polymer and its production | |
KR100697035B1 (en) | A Composition to Permanently Reshape the Hair Containing at Least One Carboxydithiol | |
KR840007713A (en) | Method for preparing a compound for treating hypertension | |
US3786076A (en) | Lipoaminoacids | |
CA2758103A1 (en) | Cyclic peptides with an anti-parasitic activity | |
JPS63105000A (en) | Acylated casein-derived polypeptide of salt thereof | |
KR20040040792A (en) | Retinol derivatives grafted with peptide and antiaging cosmetic composition containing the same | |
JPH0321001B2 (en) | ||
JPH01250344A (en) | Production of antihypertensive | |
JPH11269047A (en) | First agent for permanent wave |